GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Connect Biopharma Holdings Ltd (NAS:CNTB) » Definitions » Short-Term Debt

Connect Biopharma Holdings (Connect Biopharma Holdings) Short-Term Debt : $0.00 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Connect Biopharma Holdings Short-Term Debt?

Connect Biopharma Holdings's Short-Term Debt for the quarter that ended in Dec. 2023 was $0.00 Mil.


Connect Biopharma Holdings Short-Term Debt Historical Data

The historical data trend for Connect Biopharma Holdings's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Connect Biopharma Holdings Short-Term Debt Chart

Connect Biopharma Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Short-Term Debt
- - - - -

Connect Biopharma Holdings Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Short-Term Debt Get a 7-Day Free Trial Premium Member Only - - - - -

Connect Biopharma Holdings Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.


Connect Biopharma Holdings Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Connect Biopharma Holdings's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Connect Biopharma Holdings (Connect Biopharma Holdings) Business Description

Traded in Other Exchanges
N/A
Address
12265 El Camino Real, Suite 350, San Diego, CA, USA, 92130
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.

Connect Biopharma Holdings (Connect Biopharma Holdings) Headlines

From GuruFocus

Connect Biopharma to Participate at the Jefferies Healthcare Conference

By GuruFocusNews GuruFocusNews 06-22-2022